Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer

Biotest AG / Key word(s): Offer

Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer

07-Jan-2022 / 13:51 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)

Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer

Dreieich, 7 January 2022. In accordance with Sections 23 para. 1 sentence 1 no. 2, no. 4 of the German Securities Acquisition and Takeover Act (WpÜG), Grifiols, S.A. has today published on its website at https://www.grifols.com/en/biotest-voluntary-takeover-offer that it holds an instrument pursuant to Section 38 para. 1 sentence 1 no. 2 of the German Securities Trading Act (WpHG) relating to 17,783,776 ordinary shares, corresponding to approximately 89.88% of the voting rights in Biotest AG. Furthermore, Grifols, S.A. states in the announcement that the total number of shares of Biotest AG for which the takeover offer of Grifols, S.A. dated 26 October 2021 was accepted until the expiry of the acceptance period (4 January 2022, 24:00 hours Frankfurt am Main local time), plus the voting rights resulting from the aforementioned instrument, corresponds to approximately 95.5498 % of the voting rights and approximately 47,7749 % of the share capital of Biotest AG. The completion of the takeover offer still depends on the occurrence of several offer conditions.

According to today’s publication, Grilfols, S.A. will be, upon settlement of the takeover offer, entitled to submit an application pursuant to Section 39a para. 1 sentence 1 WpÜG for the transfer of the remaining ordinary shares of Biotest AG in exchange for a reasonable compensation by means of a court order (so called “squeeze-out”). This does not apply to preference shares of Biotest AG. In section 9.4 of the offer document published on 26 October 2021, Grifols, S.A. stated its intention, in the event that the relevant thresholds are reached, to assess the various legal options for carrying out a so-called “squeeze-out” after settlement.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Contact:
Dr. Michael Ramroth
Chief Executive Officer
Biotest AG
Landsteinerstr. 5
63303 Dreieich
Tel. +40 6103 801 225
Fax: +49 6103 801 347
michael.ramroth@biotest.com


07-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this